Exelixis Inc Foreign Currency Transaction Gain (Loss), before Tax
Exelixis Inc (EXEL) reported Foreign Currency Transaction Gain (Loss), before Tax of $900.00 thousand for the 12-month period ending 2021-01-01, per its 10-K filed 2021-02-11.
Discontinued › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2021-02-11
- Exelixis Inc foreign currency transaction gain (loss), before tax for the quarter ending 2017-12-29 was $0.00.
- Exelixis Inc foreign currency transaction gain (loss), before tax for the quarter ending 2017-09-30 was -$100.00K.
- Exelixis Inc foreign currency transaction gain (loss), before tax for the quarter ending 2017-06-30 was $0.00, a 100.00% decline year-over-year.
- Exelixis Inc foreign currency transaction gain (loss), before tax for the quarter ending 2017-03-31 was -$100.00K.
- Exelixis Inc foreign currency transaction gain (loss), before tax for fiscal 2021 was $900.00K.
- Exelixis Inc foreign currency transaction gain (loss), before tax for fiscal 2017 was -$200.00K.
- Exelixis Inc foreign currency transaction gain (loss), before tax for fiscal 2016 was -$200.00K.
- Exelixis Inc foreign currency transaction gain (loss), before tax for fiscal 2016 was -$200.00K, a 300.00% decline from fiscal 2016.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2021-01-01 | $900.00K 10-K · filed 2021-02-11 | |||
| 2017-12-29 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2018-02-26 | -$100.00K derived: sum of 2 quarters · filed 2018-02-26 | -$100.00K derived: sum of 3 quarters · filed 2018-02-26 | -$200.00K 10-K · filed 2018-02-26 |
| 2017-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$100.00K derived: sum of 2 quarters · filed 2017-11-01 | -$200.00K 10-Q · filed 2017-11-01 | -$200.00K derived: sum of 4 quarters · filed 2017-11-01 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$100.00K 10-Q · filed 2017-08-02 | -$100.00K derived: sum of 3 quarters · filed 2017-08-02 | -$200.00K derived: sum of 4 quarters · filed 2017-11-01 |
| 2017-03-31 | -$100.00K 10-Q · filed 2017-05-01 | -$100.00K derived: sum of 2 quarters · filed 2017-05-01 | -$200.00K derived: sum of 3 quarters · filed 2017-11-01 | -$100.00K derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | -$100.00K derived: sum of 2 quarters · filed 2017-11-01 | $0.00 derived: sum of 3 quarters · filed 2017-11-01 | -$200.00K 10-K · filed 2017-02-27 |
| 2016-12-30 | -$200.00K 10-K · filed 2018-02-26 | |||
| 2016-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | -$200.00K 10-Q · filed 2017-11-01 | -$200.00K derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$100.00K 10-Q · filed 2017-08-02 | -$100.00K derived: sum of 3 quarters · filed 2017-08-02 | -$54.00K derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | -$200.00K 10-Q · filed 2017-05-01 | -$200.00K derived: sum of 2 quarters · filed 2017-05-01 | -$154.00K derived: sum of 3 quarters · filed 2017-05-01 | -$300.00K derived: sum of 4 quarters · filed 2017-05-01 |
| 2016-01-01 | $100.00K 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $46.00K derived: sum of 2 quarters · filed 2017-02-27 | -$100.00K derived: sum of 3 quarters · filed 2017-02-27 | $100.00K 10-K · filed 2017-02-27 |
| 2015-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$100.00K derived: sum of 2 quarters · filed 2015-11-10 | $100.00K 10-Q · filed 2015-11-10 | $500.00K derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | $54.00K 10-Q · filed 2015-08-11 | $454.00K derived: sum of 3 quarters · filed 2017-02-27 | $588.00K derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-03-31 | $200.00K 10-Q · filed 2016-05-04 | $600.00K derived: sum of 2 quarters · filed 2017-02-27 | $734.00K derived: sum of 3 quarters · filed 2017-02-27 | $744.00K derived: sum of 4 quarters · filed 2017-02-27 |
| 2014-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $534.00K derived: sum of 2 quarters · filed 2017-02-27 | $544.00K derived: sum of 3 quarters · filed 2017-02-27 | $500.00K 10-K · filed 2017-02-27 |
| 2014-09-30 | $134.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | $144.00K derived: sum of 2 quarters · filed 2015-11-10 | $100.00K 10-Q · filed 2015-11-10 | |
| 2014-06-30 | $10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11 | -$34.00K 10-Q · filed 2015-08-11 | ||
| 2014-03-31 | -$44.00K 10-Q · filed 2015-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |